The latest price target for ACADIA Pharmaceuticals (NASDAQ: ACAD) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $42.00 expecting ACAD to rise to within 12 months (a possible 101.54% upside). 49 analyst firms have reported ratings in the last year.

The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ: ACAD) was provided by Cantor Fitzgerald, and ACADIA Pharmaceuticals reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.

While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a reiterated with a price target of $0.00 to $42.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $20.84, which is within the analyst’s predicted range.

The latest price target for ACADIA Pharmaceuticals (NASDAQ: ACAD) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $42.00 expecting ACAD to rise to within 12 months (a possible 101.54% upside). 49 analyst firms have reported ratings in the last year.

The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ: ACAD) was provided by Cantor Fitzgerald, and ACADIA Pharmaceuticals reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.

While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a reiterated with a price target of $0.00 to $42.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $20.84, which is within the analyst’s predicted range.

The latest price target for ACADIA Pharmaceuticals (NASDAQ: ACAD) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $42.00 expecting ACAD to rise to within 12 months (a possible 101.54% upside). 49 analyst firms have reported ratings in the last year.

The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ: ACAD) was provided by Cantor Fitzgerald, and ACADIA Pharmaceuticals reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.

While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a reiterated with a price target of $0.00 to $42.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $20.84, which is within the analyst’s predicted range.

The latest price target for ACADIA Pharmaceuticals (NASDAQ: ACAD) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $42.00 expecting ACAD to rise to within 12 months (a possible 101.54% upside). 49 analyst firms have reported ratings in the last year.

The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ: ACAD) was provided by Cantor Fitzgerald, and ACADIA Pharmaceuticals reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.

While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a reiterated with a price target of $0.00 to $42.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $20.84, which is within the analyst’s predicted range.

The latest price target for ACADIA Pharmaceuticals (NASDAQ: ACAD) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $42.00 expecting ACAD to rise to within 12 months (a possible 101.54% upside). 49 analyst firms have reported ratings in the last year.

The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ: ACAD) was provided by Cantor Fitzgerald, and ACADIA Pharmaceuticals reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.

While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a reiterated with a price target of $0.00 to $42.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $20.84, which is within the analyst’s predicted range.

The latest price target for ACADIA Pharmaceuticals (NASDAQ: ACAD) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $42.00 expecting ACAD to rise to within 12 months (a possible 101.54% upside). 49 analyst firms have reported ratings in the last year.

The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ: ACAD) was provided by Cantor Fitzgerald, and ACADIA Pharmaceuticals reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.

While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a reiterated with a price target of $0.00 to $42.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $20.84, which is within the analyst’s predicted range.

The latest price target for ACADIA Pharmaceuticals (NASDAQ: ACAD) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $42.00 expecting ACAD to rise to within 12 months (a possible 101.54% upside). 49 analyst firms have reported ratings in the last year.

The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ: ACAD) was provided by Cantor Fitzgerald, and ACADIA Pharmaceuticals reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.

While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a reiterated with a price target of $0.00 to $42.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $20.84, which is within the analyst’s predicted range.

The latest price target for ACADIA Pharmaceuticals (NASDAQ: ACAD) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $42.00 expecting ACAD to rise to within 12 months (a possible 101.54% upside). 49 analyst firms have reported ratings in the last year.

The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ: ACAD) was provided by Cantor Fitzgerald, and ACADIA Pharmaceuticals reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.

While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a reiterated with a price target of $0.00 to $42.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $20.84, which is within the analyst’s predicted range.